title: Temozolomide in patients with high grade gliomas.
abstract: The incidence of central nervous system neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. First-line treatment of brain tumors consists of surgery associated with radiotherapy, and followed or not by chemotherapy. When used as an adjuvant therapy after surgery and radiotherapy, chemotherapy prolongs the time to progression and the median survival time. At relapse, chemotherapy is the common therapeutic approach. In recent years, new drugs for the treatment of brain tumors have been tested, and some of them, such as temozolomide, are very promising.
authors.affiliation: Department of Medical Oncology, Azienda Ospedale-Università, Padova, Italy. brandes@ux1.unipd.it
authors.forename: A A
authors.initials: AA
authors.lastname: Brandes
authors.forename: L M
authors.initials: LM
authors.lastname: Pasetto
authors.forename: F
authors.initials: F
authors.lastname: Vastola
authors.forename: S
authors.initials: S
authors.lastname: Monfardini
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide